Pfizer's Sutent Disappoints Again - Zacks.com PDF Print
Zacks.comThe product is currently in phase III studies for advanced castration-resistant prostate cancer and for renal cell carcinoma (as adjuvant therapy). ...Pfizer's Bad Luck with Expanding Sutent's Use Continues Genetic Engineering NewsPfizer's Sutent Misses The Mark ForbesTopline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.